C4 Therapeutics Secures $20M Upfront Payment, Over $1B in Potential Milestones from New Roche Collaboration for DACs
C4 Therapeutics, Inc. (C4T) has entered into a new Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) to discover, develop, and commercialize degrader-antibody conjugates (DACs) for two initial undisclosed oncology targets. Under the terms, C4T will receive an upfront cash payment of $20.0 million and is eligible for over $1.0 billion in aggregate development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. This strategic partnership leverages C4T's expertise in targeted protein degradation and significantly de-risks the development pathway for DACs, as Roche will bear all development, regulatory, manufacturing, and commercialization costs. The agreement expands upon an existing collaboration between C4T and Roche in targeted protein degradation research that began in 2016.
Key Highlights
- C4 Therapeutics entered into a Research Collaboration and License Agreement with Roche on April 8, 2026, focusing on degrader-antibody conjugates (DACs) for two initial undisclosed oncology targets.
- C4T will receive an upfront cash payment of $20.0 million from Roche.
- The agreement includes potential aggregate development, regulatory, and commercial milestone payments exceeding $1.0 billion.
- C4T is also eligible to receive tiered royalties on net sales of any commercialized DACs.
- Roche will be responsible for all development, regulatory approval, manufacturing, and commercialization costs associated with the DAC programs.
- This new agreement builds on a pre-existing collaboration between C4T and Roche in targeted protein degradation research, which has been in place since 2016.